Sino Biopharmaceutical Limited/ADR
Sino Biopharmaceutical is a pharmaceutical group based in Wan Chai, Hong Kong, with operations in China. Its business includes modern Chinese and chemical medicines, investments, and other activities. The company develops and supplies treatments for cancer, liver disease, respiratory conditions, and surgery and pain management. Its portfolio includes branded medicines across these areas, alongside drug research and development, long-term investment activities, and healthcare and hospital businesses.
No enriched coverage for $SBMFF in the last 7 days.
No SEC Form 4 filings for $SBMFF in the last 30 days.
See all $SBMFF insider activity →Boehringer Ingelheim licensed six oncology programs from Sino Biopharmaceutical for $358M upfront, with $7B in potential milestones. Nxera Pharma licensed an EP4 agonist to AbbVie for $100M upfront, with $1.37B in potential milestones. Both deals highlight pharma's reliance on external innovation.
Sino Biopharmaceutical and Boehringer Ingelheim agreed to develop six preclinical cancer programs, with $7B in potential milestone payments. Sino will receive $358M upfront and lead early trials, while Boehringer may obtain exclusive rights post-milestones.
Sino Biopharmaceutical Limited (HKEX: 01177) launched its global brand, SBP Group, to accelerate international expansion. The company aims to globalize its product and business operations, supported by investments in R&D, partnerships, and infrastructure. It has completed deals worth over $1 billion in upfront payments and up to $7 billion in total potential value, including agreements with Sanofi and AstraZeneca.
Recent SBMFF coverage spans mergers & acquisitions and financial news.
Boehringer Ingelheim licensed six oncology programs from Sino Biopharmaceutical for $358M upfront, with $7B in potential milestones. Nxera Pharma licensed an EP4 agonist to AbbVie for $100M upfront, with $1.37B in potential milestones. Both deals highlight pharma's reliance on external innovation.
Sino Biopharmaceutical and Boehringer Ingelheim agreed to develop six preclinical cancer programs, with $7B in potential milestone payments. Sino will receive $358M upfront and lead early trials, while Boehringer may obtain exclusive rights post-milestones.
Sino Biopharmaceutical Limited (HKEX: 01177) launched its global brand, SBP Group, to accelerate international expansion. The company aims to globalize its product and business operations, supported by investments in R&D, partnerships, and infrastructure. It has completed deals worth over $1 billion in upfront payments and up to $7 billion in total potential value, including agreements with Sanofi and AstraZeneca.
AlphAI scores every news story that mentions SBMFF with an AI model for sentiment and relevance, and aggregates insider trades from Sino Biopharmaceutical Limited/ADR's SEC EDGAR Form 4 filings. Figures refresh continuously.
Boehringer Ingelheim licensed six oncology programs from Sino Biopharmaceutical for $358M upfront, with $7B in potential milestones. Nxera Pharma licensed an EP4 agonist to AbbVie for $100M upfront, with $1.37B in potential milestones. Both deals highlight pharma's reliance on external innovation.
Sino Biopharmaceutical and Boehringer Ingelheim agreed to develop six preclinical cancer programs, with $7B in potential milestone payments. Sino will receive $358M upfront and lead early trials, while Boehringer may obtain exclusive rights post-milestones.
Sino Biopharmaceutical Limited (HKEX: 01177) launched its global brand, SBP Group, to accelerate international expansion. The company aims to globalize its product and business operations, supported by investments in R&D, partnerships, and infrastructure. It has completed deals worth over $1 billion in upfront payments and up to $7 billion in total potential value, including agreements with Sanofi and AstraZeneca.
